{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"page_content": "gene expression control is especially important for gene therapies that involve highly toxic\n\npayloads such as Kid and Diphtheria toxin.\n\nAs cancers typically have more alternative splicing events compared to normal\n\ntissues, it is likely that similar splicing-based cancer-recognizing RNA switch modules exist\n\nand can be used to treat a wider range of cancers6,7. The gene therapy I described in this\n\nwork offers a new framework for improving the specificity of cancer gene therapies.\n\n156\n\n7.2 References\n\n1.\n\nArruebo, M. et al. Assessment of the Evolution of Cancer Treatment Therapies. Cancers\n\n(Basel) 3, 3279 (2011).\n\n2.\n\nReya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem\n\ncells. Nature 414, 105\u2013111 (2001).\n\n3. Waehler, R., Russell, S. J. & Curiel, D. T. Engineering targeted viral vectors for gene therapy.\n\nNat Rev Genet 8, 573\u2013587 (2007).\n\n4.\n\nPayne, K. K., Bear, H. D. & Manjili, M. H. Adoptive cellular therapy of cancer: exploring\n\ninnate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncol 10,\n\n1779\u20131794 (2014).\n\n5.\n\nPavet, V., Portal, M. M., Moulin, J. C., Herbrecht, R. & Gronemeyer, H. Towards novel\n\nparadigms for cancer therapy. Oncogene 30, 1\u201320 (2011).\n\n6.\n\nKahles, A. et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705\n\nPatients. Cancer Cell 34, 211-224.e6 (2018).\n\n7.\n\nNorth, K. et al. Synthetic introns enable splicing factor mutation-dependent targeting of\n\ncancer cells. Nat Biotechnol (2022) doi:10.1038/s41587-022-01224-2.\n\n157", "metadata": {"source": "./documents/UC Irvine/JW_Dissertation_20220824.pdf"}, "type": "Document"}}